AI and Advanced Analytics Revolutionize Genetic Toxicology Testing
Published: 20 Mar 2026
Author: Precedence Research
Key Takeaways From the 10th Impurities Summit, Milan- March 4-5, 2026
The 10th Impurities: Genotoxic, Nitrosamine and Beyond Summit took place in Milan on March 4-5, 2026. This event showcased innovative technological trends that are currently influencing genetic toxicology testing and impurity analysis in the pharmaceutical industry. Industry leaders and experts discussed effective ways to improve the detection, analysis and risk assessment of genotoxic substances in pharmaceuticals. The discussion was centered on efficiency, accuracy and regulatory requirements.
AI-Driven Impurity Profiling: The Key to Smarter Testing Decisions
One of the main areas of discussion at the summit was Artificial Intelligence-driven impurity profiling. This technology uses chemical information to foresee potential impurities with DNA damage potential, enabling pharmaceutical laboratories to prioritize testing for invitro genotoxicity. By combining AI predictions with conventional testing, such as the Ames test or micronucleus test, laboratories can concentrate testing efforts on the most dangerous substances. Industry experts at the summit pointed out that AI technologies not only boost testing speed and efficiency but also optimize data quality by reducing the risk of false positives and pointing out the subtle indicators of genotoxicity.
Next-Generation Analytical Platforms: Identifying Trace-Level Impurities
In addition to AI, the summit also focused on next-generation analytical tools. The application of high-resolution liquid chromatography mass spectrometry and real-time monitoring systems was highlighted as a means to improve the detection of trace levels of impurities. These technologies enable labs to perform more comprehensive and reliable testing while satisfying stringent regulatory demands, especially for high-throughput environments.
The global genetic toxicology testing market size was calculated at USD 2.26 billion in 2025 and is predicted to increase from USD 2.49 billion in 2026 to approximately USD 5.97 billion by 2035, expanding at a CAGR of 10.20% from 2026 to 2035 as the demand grows for fast and accurate testing of chemical and drug-induced genetic damage.
Integrating Computational Approaches
The summit also emphasized the application of in silico and predictive models as an integral component for genetic toxicology testing. The application of read-across strategies and Threshold of Toxicological Concern(TTC) approaches enables scientists to predict potential genotoxic hazards for compounds where little or no data is available. When combined with AI and high-resolution analytics, these models can also aid in the development of a robust, hybrid testing workflow.
A recent report by Precedence Research highlights that the genetic toxicology testing market is benefiting from increasing use of automated systems to improve the speed and efficiency of genetic toxicology testing.